Fertility

India's most advanced and largest IVF clinic group, Indira IVF, will offer all patients Artificial Intelligence technology to improve pregnancy outcomes

Retrieved on: 
Monday, October 24, 2022
Online, SAN, ESHRE, Genetics, Sale, Health care, Social network, American Society for Reproductive Medicine, Women's health, Reproductive medicine, Society, Patient, Privacy, Publication, Workforce, Multimedia, Infertility, Taboo, Human Reproduction (journal), European Society for Primary Immunodeficiencies, Technology, Partnership, AI, Scientific Reports, CEO, International business, IVF, Artificial intelligence, Fertility, TA Associates, ASRM, Pregnancy, Ownership, Medical device, Mineral oil, Embryology

SAN FRANCISCO, Oct. 24, 2022 /PRNewswire/ -- The largest and most advanced IVF clinic group in India, Indira IVF, will be rolling out the latest in Artificial Intelligence technology across their 100+ clinics in India in November 2022.

Key Points: 
  • SAN FRANCISCO, Oct. 24, 2022 /PRNewswire/ -- The largest and most advanced IVF clinic group in India, Indira IVF, will be rolling out the latest in Artificial Intelligence technology across their 100+ clinics in India in November 2022.
  • Life Whisperer Viability assesses how likely an embryo is to lead to a pregnancy, and Life Whisperer Genetics non-invasively assesses embryo genetic integrity.
  • Life Whisperer is currently authorized for sale in over 40 countries worldwide, with India as a key market.
  • Life Whisperer aims to improve IVF success rates at every point and, as a result, reduce time-to-pregnancy, making IVF more affordable and accessible to patients globally.

SGF research team presents 19 studies at this year's ASRM Scientific Congress, demonstrating its commitment to continuously improving outcomes for fertility patients

Retrieved on: 
Monday, October 24, 2022
Physician, Genetics, Insurance, Congress, Freezing, Georgetown University, University of Colorado, Georgetown University School of Medicine, SGF, Directorate of Research and Civil Affairs, K Street, Reproductive medicine, Society, ART, Patient, Mentorship, NIH, Eastern Virginia Medical School, Partnership, Cancer, Knowledge, University, American Society for Reproductive Medicine, Reproduction, Energy Future Holdings, AMH, National, Fertility preservation, Egg, IVF, Fertility, 2021 Essex County Council election, Gene, Infertility, University of South Florida, Nursing, Paper, ASRM, 2022, Hormone, Pharmaceutical industry, Birth control, Medical device, Hospital, MD, Research

ANAHEIM, Calif., Oct. 24, 2022 /PRNewswire-PRWeb/ -- Shady Grove Fertility's (SGF) physician-scientists will present 19 research abstracts during the 2022 American Society for Reproductive Medicine (ASRM) Scientific Congress & Expo as part of the practice's commitment to advancing knowledge and improving assisted reproductive technology (ART) treatment outcomes. This year's research by SGF presented at ASRM covered many important topics care including optimized outcomes for frozen embryo transfers, third-party reproduction, male fertility, and fertility preservation for patients with cancer, to name a few.

Key Points: 
  • Shady Grove Fertility (SGF) presents 19 studies at this year's American Society for Reproductive Medicine (ASRM) Scientific Congress & Expo, including a prize paper and 8 oral presentations.
  • SGF is one of only a few private practice fertility centers in the country to employ a full-time dedicated research team, which operates under Director of Research, Kate Devine, M.D.
  • As a premier IVF and fertility center of excellence, SGF demonstrates a sustained commitment to clinical research and clinical education.
  • SGF is among the founding partner practices of US Fertility , the largest physician-led partnership of top-tier fertility practices in the U.S.

Ovation Fertility Licenses Genomic Prediction’s LifeView PGT Platform

Retrieved on: 
Friday, October 21, 2022
Physician, Method, Risk, Life, Science, Laboratory, Parent, Family, Patient, Aneuploidy, Degenerative disease, Mosaic, Chromosome, Lists of diseases, Partnership, Cancer, NGS, Egg, IVF, Diabetes, Fertility, Genetic testing, Pregnancy loss, GLOBE, Infertility, Child, PGT, Pregnancy, Vaccine, Birth control, Mineral oil, Pharmaceutical industry, MD

By licensing the companys LifeViewTM PGT platform for use in Ovation Genetics labs, Ovation will be able to offer physicians and patients the most comprehensive preimplantation genetic testing (PGT) available to aid in the selection of optimal-quality embryos for transfer as part of IVF.

Key Points: 
  • By licensing the companys LifeViewTM PGT platform for use in Ovation Genetics labs, Ovation will be able to offer physicians and patients the most comprehensive preimplantation genetic testing (PGT) available to aid in the selection of optimal-quality embryos for transfer as part of IVF.
  • With five LifeView PGT options, Ovation will enhance and expand its PGT capabilities to provide even better outcomes for physicians and patients.
  • Ovation Fertility is pleased to partner with Genomic Prediction to expand the availability of the LifeView platform to Ovations genetic testing clients.
  • Learn more about Genomic Prediction's LifeView PGT testing at www.lifeview.com.

Progyny, Inc. Announces Details for Its Third Quarter 2022 Results Report

Retrieved on: 
Tuesday, October 18, 2022
Physician, Growth, Science, PCA, Education, Patient, CNBC, Nasdaq, GLOBE, Fertility, Child, Leadership, Internet service provider, Health care

NEW YORK, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a leading benefits management company specializing in fertility and family building benefits solutions, will report its financial results for the quarterly period ended September 30, 2022 after the close of the market on Thursday, November 3, 2022.

Key Points: 
  • NEW YORK, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a leading benefits management company specializing in fertility and family building benefits solutions, will report its financial results for the quarterly period ended September 30, 2022 after the close of the market on Thursday, November 3, 2022.
  • The company will host a conference call at 4:45 P.M. Eastern Time (1:45 P.M. Pacific Time) and issue a press release regarding its financial results prior to the start of the call.
  • An audio replay of the call will be available through Thursday, November 10, 2022 and may be accessed by dialing 1.800.332.6854 (U.S. participants) or 1.973.528.0005 (international participants) with the passcode 265484.
  • We are redefining fertility and family building benefits, proving that a comprehensive and inclusive solution can simultaneously benefit employers, patients, and physicians.

Helsinn publishes new data evaluating chlormethine gel’s mode of action in Dermatology and Therapy

Retrieved on: 
Tuesday, October 18, 2022
Mycosis fungoides, Birth, Caregiver, Skin, Birth control, Smoking, Journal of Investigative Dermatology, Corporation, Blistering, Woman, Blister, Water, Dermis, Epidermis, Environment, Fertility, Fetus, Mycosis, Visual impairment, European Commission, Ulcer, Photophobia, Infertility, Permeation, Inflammation, Chlormethine, Red, Cancer, Medical Affairs Bureau, JAMA Dermatology, IB, Hypersensitivity, Itch, FDA, Dermatology, Female, Risk, Growth, Dermatitis, Research, Respect, Eye injury, Pain, Ageing, Royal commission, Nasal mucosa, Hyperpigmentation, Patient, Burns, Anaphylaxis, T-cell lymphoma, Swelling, CL, Toxicity, Adult, Safety, Heart, Pharmaceutical industry, Medical device, Medical imaging, Vaccine, Dentistry, EU

This article, Chlormethine Gel for the treatment of Mycosis Fungoides Cutaneous T-Cell Lymphoma: In Vitro Release and Permeation Testing, evaluated part of the mode of action of chlormethine (CL) gel once applied to the skin.

Key Points: 
  • This article, Chlormethine Gel for the treatment of Mycosis Fungoides Cutaneous T-Cell Lymphoma: In Vitro Release and Permeation Testing, evaluated part of the mode of action of chlormethine (CL) gel once applied to the skin.
  • In a preliminary, proof-of-concept, in vitro study, the release profile of 0.016% chlormethine gel was evaluated compared to an ointment-based formulation of CL.
  • Title: Chlormethine Gel for the treatment of Mycosis Fungoides Cutaneous T-Cell Lymphoma: In Vitro Release and Permeation Testing.
  • Understanding CL gels mode of action and how it permeates through the skin is extremely important for its use in clinical practice.

Europe Probiotic Supplements Market Report 2022: Increasing Preventive Healthcare Expenditure in Europe Drives Growth - ResearchAndMarkets.com

Retrieved on: 
Thursday, October 20, 2022
Vitamins, Supplements, Health, Allergy, Lactobacillus, Defecation, Risk, Acid, Woman, Infection, Distribution, Immunity, CAGR, Probiotic, Mother, Vaginitis, Inflammation, Personal lubricant, Health, Menopause, US, Weight gain, Colic, Genetics, Fertility, Dermatitis, Diet, Pregnancy, COVID-19, Bloating, Dietary supplement

The Europe probiotic supplements market growth is driven by the rising focus of women on digestive, genital, and immune health.

Key Points: 
  • The Europe probiotic supplements market growth is driven by the rising focus of women on digestive, genital, and immune health.
  • Thus, this factor is expected to significantly drive the Europe probiotic supplements market growth in the coming years.
  • According to the International Probiotics Association's report, in 2019, around 63% of the consumers of probiotic supplements in Europe were women.
  • Thus, this factor is expected to significantly drive the Europe probiotic supplements market in the coming years.

INVOcell Review Published in Current Opinion in Obstetrics and Gynecology

Retrieved on: 
Friday, October 21, 2022
Fertility clinic, Insemination, Current Opinion, Securities Act of 1933, Culture, Review, NASDAQ, Patient, ART, IUI, Multimedia, ICSI, Fertilisation, Private Securities Litigation Reform Act, Oocyte, Company, Securities Exchange Act of 1934, IVF, Fertility, Literature, IVC, Mineral oil, Birth control, Obstetrics, Gynaecology

The review, titled "Intravaginal embryo culture: a successful alternative to standard IVF that may improve access to care," by Dr. Amber R. Cooper was published in the Current Opinion in Obstetrics and Gynecology.

Key Points: 
  • The review, titled "Intravaginal embryo culture: a successful alternative to standard IVF that may improve access to care," by Dr. Amber R. Cooper was published in the Current Opinion in Obstetrics and Gynecology.
  • A copy of the publication is available at:
    Intravaginal embryo culture: a successful alternative to sta... : Current Opinion in Obstetrics and Gynecology (lww.com) .
  • Current Opinion in Obstetrics and Gynecology is a bimonthly publication offering a unique and wide ranging perspective on the key developments in the field.
  • Each issue features hand-picked review articles from our team of expert editors.

Ferring Pharmaceuticals Announces the Launch of FertilityWise - a New, On-Demand E-Learning Program for Fertility Clinic Staff

Retrieved on: 
Friday, October 21, 2022
Physician, Cryopreservation, American Medical Group Association, Growth, Maternal health, Parent, Diversity, Reproductive medicine, Mother, Patient, Gastroenterology, MPH, Instagram, EFront (eLearning software), Technology, Knowledge, DEI, E-sign, Software, Curriculum, Ferring Pharmaceuticals, Medication, Fertility, Nursing, Medicine, Facebook, Ferring

This new offering underscores Ferring's commitment to helping educate healthcare providers by compiling innovative, evidence-based content related to fertility care into easy-to-access modules.

Key Points: 
  • This new offering underscores Ferring's commitment to helping educate healthcare providers by compiling innovative, evidence-based content related to fertility care into easy-to-access modules.
  • PARSIPPANY, N.J., Oct. 21, 2022 /PRNewswire/ -- Ferring Pharmaceuticals U.S. today announced the launch of FertilityWise, a digital, on-demand series of e-learning modules developed specifically for fertility nurses and advanced practice providers.
  • Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group committed to helping people around the world build families and live better lives.
  • Nearly half of fertility patients in the US, Canada, and UK use EngagedMD's eLearn and eSign tools during their fertility journey.

US Fertility launches Research Division to further advance scientific and medical research in the field of reproductive medicine

Retrieved on: 
Thursday, October 20, 2022
Editorial board, British Rail Research Division, REI, Culture, Georgetown University School of Medicine, Science, W. Alton Jones Foundation, Reproductive medicine, Society, Patient, Research, NIH, Region, Program, Episcopal conference, Partnership, Expo, Technology, San Francisco Bay Area, American Society for Reproductive Medicine, Biostatistics, FCI, National, SART, Assisted reproductive technology, IVF, Quality assurance, Fertility, 2021 Essex County Council election, Medicine, RSC, ASRM, Pregnancy, Medical device, Birth control, Infertility

ROCKVILLE, Md., Oct. 20, 2022 /PRNewswire-PRWeb/ -- US Fertility's newly formed Research Division will conduct and publish high-quality research studies to advance the field of reproductive medicine to provide better, more effective care to patients in the future.

Key Points: 
  • , Executive Medical Director and Chief Research Officer at US Fertility, in close collaboration with Luis Hoyos, M.D.
  • , Regional Research Director and practicing reproductive endocrinologist (REI) at US Fertility founding partner practice IVF Florida ; Michael Homer, M.D.
  • Dr. Devine is a practicing, board-certified reproductive endocrinologist and fertility physician at Shady Grove Fertility , a founding partner practice of US Fertility.
  • Visit the US Fertility Research Division landing page to learn more about the program and discover the latest research in the field of reproductive medicine.

Ovation Fertility Licenses Genomic Prediction's LifeView PGT to Provide Patients with the Most Advanced Testing Available

Retrieved on: 
Thursday, October 20, 2022
Method, Genetic counseling, CSO, Risk, Laboratory, Family, Parent, Adult, Patient, Aneuploidy, Genetic testing, Mosaic, Comparison, Cancer, Ovation, NGS, Egg, IVF, Fertility, Physician, Gene, Genetics, Clinical trial, Infertility, Cell division, PGT, Pregnancy, Scores, Birth control, Pharmaceutical industry, Medical device

"This collaboration will provide Ovation patients with access to state-of-the-art technology and improved clinical care," said Paul Kappelman, chief executive officer of Ovation Fertility.

Key Points: 
  • "This collaboration will provide Ovation patients with access to state-of-the-art technology and improved clinical care," said Paul Kappelman, chief executive officer of Ovation Fertility.
  • With LifeView PGT for structural rearrangements (PGT-SR), patients have the option to select an embryo that does not carry the same balanced translocation that they do.
  • Physicians partner with Ovation to offer their patients advanced preconception carrier screening; preimplantation genetic testing; donor egg and surrogacy services; and secure storage for their frozen eggs, embryos and sperm.
  • Learn more about Genomic Prediction's LifeView PGT testing at: www.lifeview.com
    Wiemer et al.